ZVRAZevra Therapeutics, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~4% a year FCF growth. The price demands less than its three-year revenue growth of 102% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ZVRA's price assumes
Zevra Therapeutics, Inc. trades at 10.6× earnings against 19.8× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 19.8 · cheaper than the typical name in its group
- Price / sales
- 6.46
Price / sales · as of 2026-Q2
- Free cash flow yield
- 5.6%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- +4.2%
Growth the price implies · The price pays for +4.2% free cash flow growth a year for a decade; revenue has grown 102% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 4.04
- EV / EBITas of 2026-Q2
- 7.99
- EV / salesas of 2026-Q2
- 4.84
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Free cash flow, trailing twelve months
- $33M
- Market capitalisation59.4 million shares, counted Jul 31, 2026
- $581M
- 3-year revenue growth
- +102%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.